NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
CAMBRIDGE, Mass., September 01, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address…
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for…
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
LONDON & NEW YORK, September 01, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today…
Psilocybin as a Novel Therapy for Residual Anhedonia (NCT07607938, psilocybin)
This Phase I, randomised, triple-masked, parallel-group trial (n=90) will evaluate whether a single oral dose of psilocybin 25 mg can improve residual anhedonia and emotional blunting in adults with major depressive d...
Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD
This qualitative case comparison (n=6) examined three responders and three non-responders after psilocybin (0.25 mg/kg) with psychological support for treatment-resistant OCD. Responders described surrender, self-comp...
Safety, tolerability, and pharmacokinetics of oral Ketamir-2, a novel selective NMDA receptor antagonist: results of a first-in-human Phase 1 study
This preprint reports a first-in-human, randomised, double-blind, placebo-controlled Phase I trial of oral Ketamir-2 in 57 healthy adults. Single doses of 50–600 mg and daily doses of 150–600 mg for five days produced...
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants Wi… (NCT07570654, psilocybin)
This Phase II/III, multicentre, randomised, double-blind, controlled trial (n=300) will evaluate the efficacy, safety and tolerability of COMP360 psilocybin in adults with post-traumatic stress disorder (PTSD). The st...
A study of 27 healthy adults found that DMT shifted brain activity towards more random, less complex patterns, with larger changes linked to stronger ego dissolution.
Across two studies, DMT reduced criticality in theta, alpha and beta brain waves, moving signals away from the balance between order and chaos. The size of this shift correlated with participants’ reported intensity o...
Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD
This qualitative case comparison (n=6) examined three responders and three non-responders after psilocybin (0.25 mg/kg) with psychological support for treatment-resistant OCD. Responders described surrender, self-comp...
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD (NCT06349083, psilocybin)
This double-blind, randomized, placebo-controlled Phase II trial (n=200) investigates the therapeutic neural mechanisms of psilocybin (30mg) in patients with alcohol use disorder (AUD).
Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) (NCT06378528, ketamine)
This interventional trial (n=5) investigates the safety and feasibility of ketamine-assisted psychotherapy in adolescents with posttraumatic stress disorder (PTSD).
Safety, tolerability, and pharmacokinetics of oral Ketamir-2, a novel selective NMDA receptor antagonist: results of a first-in-human Phase 1 study
This preprint reports a first-in-human, randomised, double-blind, placebo-controlled Phase I trial of oral Ketamir-2 in 57 healthy adults. Single doses of 50–600 mg and daily doses of 150–600 mg for five days produced...
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage…
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK, August 31, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address…
Prozac Lessons: 5 Questions for drug historian David Herzberg
Herzberg discusses the history of “mind medicines” like Prozac and parallels between antidepressants and psychedelics.